Masimo Corporation Common Stock (MASI)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for understandable businesses with durable advantages and a sensible price. Masimo sells patient-monitoring and connectivity technology, a specialized healthcare niche. The quality signs are real: FairStock calculates return on equity of 24.99%, a Piotroski F-score of 6/9, debt-to-equity of 0.62, and an Altman Z-score of 8.56. Trailing free cash flow is $206.1M. But the price is the problem. At the 2026-06-12 close of $179.95, FairStock puts the shares at 44.54 times earnings, 11.95 times book, 28.17 times EV/EBITDA, and a 2.2% free cash flow yield. Its Graham Number is $37.01, producing a margin of safety of -386.22%. The latest filed quarter—fiscal Q1 2026—showed revenue of $403.6M and net income of $57.1M, a 14.15% margin. The data also list revenue growth of -31.33% and profit growth of 119.54%, though no period is named for those growth rates. ROCE of 10.20% is modest next to ROE. FairStock gives no Lynch category because only 0 years of filed results exist and 3 are needed. Overall: a profitable, financially sturdy company, but the valuation leaves no room for error.

In plain English: Masimo makes patient-monitoring devices and connectivity tools used in healthcare. The company is profitable and financially strong, but its sales have recently fallen sharply and the stock price looks expensive compared with its profits and accounting value. It appears to be a good business trading at a rich price with uneven momentum.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-06-12 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer